

INDUSTRY EXECUTIVE SEMINAR SERIES

Jon T. Holmlund, M.D.
Chief Medical Officer
Senior Vice President, Development
Ascenta Therapeutics, Inc.



Monday, April 30, 2007
2:00pm-3:30pm
Keck Amphitheater, Beckman Center

Dr. Holmlund joined Ascenta (www.ascenta.com) in April, 2004 and is Chief Medical Officer and Senior Vice President, Clinical and Regulatory Affairs. Prior to Ascenta, Dr. Holmlund was Vice President of Development at Isis Pharmaceuticals, Inc., where he was in charge of the clinical development organization and responsible for drug development and overall budgetary and portfolio management across all therapeutic areas, including oncology, rheumatology, inflammatory bowel disease, diabetes, hepatitis, and lipid metabolism. He led the development of five drug candidates in oncology, including one drug that completed Phase III studies. Prior to Isis, Dr. Holmlund was a Senior Investigator in the Cancer Therapy Evaluation and Biological Response Modifiers Programs of the National Cancer Institute (NCI), where he oversaw translational and clinical development of monoclonal antibodies, cytokines, cancer vaccines, and other biologic strategies to treat cancer. He also was a clinical investigator on a number of intramural NCI trials during his tenure there. Dr. Holmlund received his M.D. degree from the State University of New York at Buffalo, and completed his training in internal medicine and hematology/oncology at George Washington University Medical Center in Washington, D.C.

SEMINAR HIGHLIGHTS:

- Ascenta's science and the current Ph.D. scientists that drive the company.
- Ascenta's future positioning in the Global and San Diego BioPharma markets and the Ph.D. scientists needed to get there.
- Dr. Holmlund's story: "How I found a scientific career in industry."

